Rock Springs Capital Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-835,776
| Closed | -$49.1M | – | 120 |
|
|
2023
Q4 | $49.1M | Sell |
835,776
-295,431
| -26% | -$16.6M | 1.21% | 27 |
|
|
2023
Q3 | $49.3M | Buy |
1,131,207
+9,560
| +0.9% | +$341K | 1.32% | 27 |
|
|
2023
Q2 | $40.5M | Buy |
1,121,647
+56,386
| +5% | +$2.32M | 0.96% | 36 |
|
|
2023
Q1 | $39.6M | Buy |
1,065,261
+260,237
| +32% | +$11.7M | 0.95% | 38 |
|
|
2022
Q4 | $36.5M | Sell |
805,024
-61,752
| -7% | -$4M | 0.88% | 41 |
|
|
2022
Q3 | $60.5M | Buy |
866,776
+21,799
| +3% | +$1.61M | 1.56% | 19 |
|
|
2022
Q2 | $56.7M | Buy |
844,977
+285,243
| +51% | +$18.1M | 1.65% | 18 |
|
|
2022
Q1 | $46M | Buy |
559,734
+149,319
| +36% | +$15.3M | 1.16% | 32 |
|
|
2021
Q4 | $60.2M | Buy |
410,415
+56,901
| +16% | +$8.83M | 1.39% | 20 |
|
|
2021
Q3 | $62.5M | Buy |
353,514
+34,429
| +11% | +$5.54M | 1.32% | 24 |
|
|
2021
Q2 | $51.5M | Sell |
319,085
-4,562
| -1% | -$732K | 1.02% | 30 |
|
|
2021
Q1 | $55.4M | Sell |
323,647
-49,505
| -13% | -$9.8M | 1.21% | 26 |
|
|
2020
Q4 | $82M | Buy |
373,152
+24,391
| +7% | +$5.27M | 1.74% | 12 |
|
|
2020
Q3 | $57.9M | Hold |
348,761
| – | – | 1.47% | 18 |
|
|
2020
Q2 | $39.8M | Buy |
348,761
+7,261
| +2% | +$704K | 1.09% | 34 |
|
|
2020
Q1 | $26.3M | Buy |
341,500
+41,500
| +14% | +$3.72M | 1.09% | 37 |
|
|
2019
Q4 | $38.7M | Buy |
300,000
+42,500
| +17% | +$4.1M | 1.22% | 24 |
|
|
2019
Q3 | $20.1M | Buy |
257,500
+55,000
| +27% | +$5.16M | 0.8% | 48 |
|
|
2019
Q2 | $20.9M | Buy |
202,500
+22,500
| +13% | +$1.75M | 0.75% | 50 |
|
|
2019
Q1 | $13.2M | Buy |
180,000
+30,000
| +20% | +$2.04M | 0.51% | 66 |
|
|
2018
Q4 | $6.36M | Sell |
150,000
-90,000
| -38% | -$3.59M | 0.3% | 85 |
|
|
2018
Q3 | $11.3M | Hold |
240,000
| – | – | 0.41% | 79 |
|
|
2018
Q2 | $11.8M | Buy |
240,000
+51,000
| +27% | +$1.93M | 0.46% | 75 |
|
|
2018
Q1 | $5.8M | Buy |
189,000
+9,000
| +5% | +$250K | 0.25% | 110 |
|
|
2017
Q4 | $3.29M | Buy |
+180,000
| New | +$2.79M | 0.15% | 120 |
|
Other funds holding MRTX
Rock Springs Capital Management's MRTX Position: Q1 2024 in Review
Rock Springs Capital Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 835,776 shares — an estimated $49.1M sold.
Rock Springs Capital Management first reported a position in MRTX in Q4 2017 and held it in 25 quarters. The position peaked at $82M in Q4 2020. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.
- Rock Springs Capital Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
- Rock Springs Capital Management sold 835,776 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $49.1M.
- Rock Springs Capital Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2017 and held it in 25 quarters.
- Rock Springs Capital Management's Mirati Therapeutics, Inc. Common Stock position peaked at $82M in Q4 2020.
- 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.
Based on Rock Springs Capital Management's 13F filing for Q1 2024, filed 15 May 2024.